Showing 1 to 12 of 68 results
Novo Nordisk Partners with Pocketpills for Ozempic and Wegovy Home Delivery
Novo Nordisk Canada has partnered with Pocketpills, a Canadian online pharmacy, to offer home delivery of its diabetes and obesity drugs, Ozempic and Wegovy, streamlining the ordering process and providing discounts.
Novo Nordisk Partners with Pocketpills for Ozempic and Wegovy Home Delivery
Novo Nordisk Canada has partnered with Pocketpills, a Canadian online pharmacy, to offer home delivery of its diabetes and obesity drugs, Ozempic and Wegovy, streamlining the ordering process and providing discounts.
Progress
16% Bias Score
CVS Faces Class-Action Lawsuit Over Obesity Drug Coverage
A class-action lawsuit targets CVS Caremark for removing coverage of Eli Lilly's Zepbound, replacing it with Novo Nordisk's Wegovy, despite medical professionals arguing the drugs aren't interchangeable, impacting an estimated 25-30 million people.
CVS Faces Class-Action Lawsuit Over Obesity Drug Coverage
A class-action lawsuit targets CVS Caremark for removing coverage of Eli Lilly's Zepbound, replacing it with Novo Nordisk's Wegovy, despite medical professionals arguing the drugs aren't interchangeable, impacting an estimated 25-30 million people.
Progress
24% Bias Score
Denmark's Economic Growth Forecast Halved Due to Novo Nordisk's Slowdown
Denmark's economic growth forecast for 2025 has been cut in half to 1.4 percent, primarily due to lower-than-expected sales of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, after a 3.7 percent growth in 2023 driven by pharmaceutical exports.
Denmark's Economic Growth Forecast Halved Due to Novo Nordisk's Slowdown
Denmark's economic growth forecast for 2025 has been cut in half to 1.4 percent, primarily due to lower-than-expected sales of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, after a 3.7 percent growth in 2023 driven by pharmaceutical exports.
Progress
20% Bias Score
Novo Nordisk Halves Ozempic Price for Uninsured Americans
Novo Nordisk slashed Ozempic's price by over 50% to $499/month for three doses for uninsured Americans, available via its website and GoodRx, following political pressure and shortages of the semaglutide active ingredient.
Novo Nordisk Halves Ozempic Price for Uninsured Americans
Novo Nordisk slashed Ozempic's price by over 50% to $499/month for three doses for uninsured Americans, available via its website and GoodRx, following political pressure and shortages of the semaglutide active ingredient.
Progress
36% Bias Score
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
Progress
40% Bias Score
Novo Nordisk Shares Plunge on Lowered Profit Outlook Amidst Copycat Drug Competition
Novo Nordisk shares fell over 20% on Tuesday after the company announced a new CEO and lowered its profit expectations, citing weaker sales of its weight-loss drug Wegovy due to competition from copycat drugs; the company expects 8%-14% sales growth and 10%-16% operating profit growth for 2025.
Novo Nordisk Shares Plunge on Lowered Profit Outlook Amidst Copycat Drug Competition
Novo Nordisk shares fell over 20% on Tuesday after the company announced a new CEO and lowered its profit expectations, citing weaker sales of its weight-loss drug Wegovy due to competition from copycat drugs; the company expects 8%-14% sales growth and 10%-16% operating profit growth for 2025.
Progress
44% Bias Score
High Dropout Rate Among Weight Loss Drug Users
A new analysis reveals that 52 percent of over 77,000 people using anti-obesity drugs in Denmark stopped within a year, raising concerns about long-term adherence and highlighting socioeconomic disparities in access.
High Dropout Rate Among Weight Loss Drug Users
A new analysis reveals that 52 percent of over 77,000 people using anti-obesity drugs in Denmark stopped within a year, raising concerns about long-term adherence and highlighting socioeconomic disparities in access.
Progress
20% Bias Score
Denmark's Economic Growth Forecast Cut in Half Amidst Novo Nordisk Slowdown
Denmark's 2025 economic growth forecast has been slashed from 3% to 1.4% due to weaker-than-expected performance by Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, resulting from increased competition, inventory buildup, and new US tariffs.
Denmark's Economic Growth Forecast Cut in Half Amidst Novo Nordisk Slowdown
Denmark's 2025 economic growth forecast has been slashed from 3% to 1.4% due to weaker-than-expected performance by Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, resulting from increased competition, inventory buildup, and new US tariffs.
Progress
20% Bias Score
Weight-Loss Injections Reshape UK Wedding Dress Industry
The surge in popularity of weight-loss injections like Ozempic and Wegovy in the UK is causing significant challenges for bridal businesses, as brides' rapid weight loss necessitates expensive and time-consuming last-minute alterations.
Weight-Loss Injections Reshape UK Wedding Dress Industry
The surge in popularity of weight-loss injections like Ozempic and Wegovy in the UK is causing significant challenges for bridal businesses, as brides' rapid weight loss necessitates expensive and time-consuming last-minute alterations.
Progress
16% Bias Score
Novo Nordisk's Share Price Plummets Amidst Increased Competition and Market Challenges
Novo Nordisk's share price plummeted over 50 percent this year due to increased competition from Eli Lilly's Mounjaro, the prevalence of cheaper compounded GLP-1 drugs, and slower adaptation to market changes, leading to a significant loss in market value and a CEO change.
Novo Nordisk's Share Price Plummets Amidst Increased Competition and Market Challenges
Novo Nordisk's share price plummeted over 50 percent this year due to increased competition from Eli Lilly's Mounjaro, the prevalence of cheaper compounded GLP-1 drugs, and slower adaptation to market changes, leading to a significant loss in market value and a CEO change.
Progress
56% Bias Score
Weight-Loss Injections Increase Surgical Death Risk
A London-based plastic surgeon warns that the widespread use of weight-loss injections in the UK is creating an increased risk of death during surgery due to delayed gastric emptying, causing aspiration pneumonia, and emphasizes the need for patients to inform doctors about their usage.
Weight-Loss Injections Increase Surgical Death Risk
A London-based plastic surgeon warns that the widespread use of weight-loss injections in the UK is creating an increased risk of death during surgery due to delayed gastric emptying, causing aspiration pneumonia, and emphasizes the need for patients to inform doctors about their usage.
Progress
60% Bias Score
Forged Prescriptions for Weight-Loss Drugs Rise in Northern Germany
Criminals in northern Germany are forging prescriptions for weight-loss medications like Ozempic and Wegovy, exploiting high demand fueled by social media trends and celebrity endorsements; the introduction of e-prescriptions is reducing but not eliminating the problem, leaving pharmacies financiall...
Forged Prescriptions for Weight-Loss Drugs Rise in Northern Germany
Criminals in northern Germany are forging prescriptions for weight-loss medications like Ozempic and Wegovy, exploiting high demand fueled by social media trends and celebrity endorsements; the introduction of e-prescriptions is reducing but not eliminating the problem, leaving pharmacies financiall...
Progress
36% Bias Score
Showing 1 to 12 of 68 results